SAN
DIEGO, Oct. 17, 2022 /PRNewswire/ -- NuVasive,
Inc. (NASDAQ: NUVA), the leader in spine technology innovation,
focused on transforming spine surgery with minimally disruptive,
procedurally integrated solutions, today announced it will continue
its partnership with EUROSPINE as a gold sponsor and will attend
EUROSPINE 2022 held October 19 to 21
in Milan.
"Our support of EUROSPINE reflects our belief in partnering with
the most influential societies, study groups and congresses around
the globe to advance better spine care and change the lives of more
patients," said Chris Barry, chief executive
officer at NuVasive. "Through our industry-leading set of
procedural solutions, enabled by the technologies within Pulse, we
continue to build the future of spine care to deliver more
intelligent surgery."
NuVasive will host a lunch
workshop, Pulse®: Where accuracy meets
innovation, on Wednesday, October
19 from 11:45 to 13:45 CEST in Room Brown
2 of Milano Convention Centre. Mr. Morgan Jones, Royal Orthopaedic Hospital,
National Health Service Trust and Birmingham Children's Hospital,
and Dr. Sven Vetter, BG Klinik
Ludwigshafen, will demonstrate how Pulse has impacted their
operating rooms (OR) with its navigation accuracy. Surgeons will
also have the opportunity for demonstrations of Pulse and Siemens
Healthineers' Cios Spin at the NuVasive stand, seeing first-hand
how the two support a more efficient navigation workflow in the
OR.
NuVasive stand #98 will feature several Meet the
Expert sessions:
- Pulse: An expert's review of its modalities—Join Dr.
Sven Vetter on Wednesday, October 19, as he presents Pulse, an
enabling technology platform that integrates intraoperative
neuromonitoring, global alignment, rod bending, radiation reduction
and imaging enhancement, and navigation.
- Reline® 3D: An expert's guide to 3D deformity
correction—Join Mr. Stewart Tucker,
Great Ormond Street Hospital, on Thursday,
October 20, as he presents Reline 3D, a posterior fixation
system optimized to address three-dimensional deformity present in
the spine.
- X360™: An expert's journey with single-position
surgery (SPS)—Join Prof. Dr. Dominique A.
Rothenfluh, Lausanne University Hospital, on Friday, October 21, as he presents X360, a
comprehensive lateral approach to SPS that leverages advanced
techniques and technologies to help surgeons deliver
patient-specific surgical plans while enhancing OR workflow and
efficiency.
For more information, please visit the NuVasive EUROSPINE
webpage here.
About NuVasive
NuVasive, Inc. (NASDAQ: NUVA) is the leader in spine
technology innovation, with a mission to transform surgery, advance
care, and change lives. The Company's less-invasive, procedurally
integrated surgical solutions are designed to deliver reproducible
and clinically proven outcomes. The Company's comprehensive
procedural portfolio includes surgical access instruments, spinal
implants, fixation systems, biologics, software for surgical
planning, navigation and imaging solutions, magnetically adjustable
implant systems for spine and orthopedics, and intraoperative
neuromonitoring technology and service offerings. With more
than $1 billion in net sales, NuVasive operates
in more than 50 countries serving surgeons, hospitals, and
patients. For more information, please
visit www.nuvasive.com.
Forward-Looking
Statements
NuVasive cautions you that statements included in this news
release that are not a description of historical facts are
forward-looking statements that involve risks, uncertainties,
assumptions and other factors which, if they do not materialize or
prove correct, could cause NuVasive's results to differ
materially from historical results or those expressed or implied by
such forward-looking statements. The potential risks and
uncertainties which contribute to the uncertain nature of these
statements include, among others, risks associated with acceptance
of the Company's surgical products and procedures by spine surgeons
and hospitals, development and acceptance of new products or
product enhancements, clinical and statistical verification of the
benefits achieved via the use of NuVasive's products, the
Company's ability to adequately manage inventory as it continues to
release new products, its ability to recruit and retain management
and key personnel, and the other risks and uncertainties described
in NuVasive's news releases and periodic filings with
the Securities and Exchange
Commission. NuVasive's public filings with
the Securities and Exchange Commission are available
at www.sec.gov. NuVasive assumes no obligation to
update any forward-looking statement to reflect events or
circumstances arising after the date on which it was
made.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/nuvasive-to-sponsor-and-participate-at-eurospine-2022-301649953.html
SOURCE NuVasive, Inc.